🇺🇸 FDA
Pipeline program

PF-05280602

B3051001

Phase 1 mab completed

Quick answer

PF-05280602 for Hemophilia A is a Phase 1 program (mab) at CATALYST PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
CATALYST PHARMACEUTICALS, INC.
Indication
Hemophilia A
Phase
Phase 1
Modality
mab
Status
completed

Clinical trials